60910 Federal Register / Vol. 62, No. 219 / Thursday, November 13, 1997 / Notices

The normal gene and its mutations may

also be useful for studying and

controlling inflammation.

Methods for Inactivating Enveloped

RNA Virus Particles and Compositions

for Use Therewith

HF Rosenberg, JB Domachowske

(NIAID)

Serial Number: 60/052,986 filed 02 Jul

97

Licensing Contact: Robert Benson, 301/

496–7056 ext. 267

The inventors have discovered that

treatment of enveloped single-stranded

RNA viruses with eosinophil-derived

neurotoxin (EDN), a ribonuclease,

inactivates the viruses in cell culture.

Respiratory Syncytial Virus (RSV) and

Parainfluenza Virus (PIV) are medically

the most important enveloped RNA

viruses; together they hospitalize over

100,000 infants per year in the US. EDN

is the major eosinophil ribonuclease. It

has been cloned and recombinant EDN

is available. Despite its name, EDN is

not toxic to respiratory epithelial or

other somatic cells. Both parenteral and

aerosol administration are

contemplated. Claimed are methods of

treatment and pharmaceutical

compositions.

Actinomycin D: A New Use for AIDS

Therapy

JG Levin, J Guo (NICHD)

Serial No. 60/047,223 filed 20 May 97

Licensing Contact: Robert Benson, 301/

496–7056 ext. 267

This invention is a method of treating

HIV infection by administering

Actinomycin D. In a broader sense the

invention is the discovery of a new

target for anti-HIV therapy, namely the

inhibition of the first strand transfer

step in reverse transcription, an early

step in HIV replication. Actinomycin D,

a licensed drug used to treat Wilm’s

tumor, inhibits the first strand transfer

step at a concentration estimated to be

an order of magnitude lower than that

used to treat cancer, as shown by

inhibition studies with purified reverse

transcriptase and detergent-treated HIV

virions.

Rapid Method for Diagnosing the

Various Forms of Alpha-Thalassemia

GP Rodgers, DC Tang (NIDDK)

Serial No. 60/031,880 filed 27 Nov 96

Licensing Contact: J. Peter Kim, 301/

496–7056 ext. 264

The present invention is directed to a

simple, inexpensive, and rapid method

for detecting thalassemias. The present

invention provides for the identification

of nucleic acid primers capable of

detecting and distinguishing between

the various forms of alpha-thalassemia

using any biological material (dry or

fluid) containing nucleic acid material.

The invention further provides for a

method and diagnostic kit for the

detection and quantitation of

hemoglobin (Hb) alpha gene(s) in alphathalassemia patients, a method and kit

for screening for carriers of this genetic

disorder, a sensitive non-radioisotopic

test capable of differentiating between

the various forms of thalassemia, and a

means to identify persons who are at

risk of having offspring with

homozygous alpha-thalassemia.

Dated: November 4, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 97–29843 Filed 11–12–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and

Human Development; Notice of

Meeting of the National Advisory

Board on Medical Rehabilitation

Research

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the meeting of the

National Advisory Board on Medical

Rehabilitation Research, National

Institute of Child Health and Human

Development, November 24–25, 1997,

Natcher Conference Center, Conference

Rooms E1–E2, Bethesda, Maryland.

The meeting will be open to the

public from 8:00 a.m. to 5:00 p.m. on

November 24 and 8:00 a.m. to

adjournment on November 25.

Attendance by the public will be limited

to space available. Board topics will

include: (1) A report on fiscal issues

concerning the National Center for

Medical Rehabilitation Research

(Center) and the Institute; (2) reports on

the program activities of the Center; (3)

a discussion of general priority areas of

research for the Center; and (4) a

discussion of support for medical

rehabilitation research by government

agencies.

Ms. Debbie Welty, Board Secretary,

NICHD, 6100 Building, Room 2A03,

National Institutes of Health, Bethesda,

Maryland 20892, Area Code 301–402–

2242, will provide a summary of the

meeting and a roster of Advisory Board

members as well as substantive program

information. Individuals who plan to

attend and need special assistance, such

as sign language interpretation or other

reasonable accommodations, should

contact Ms. Welty.

Dated: November 6, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–29847 Filed 11–12–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Cancer Institute Special

Emphasis Panel (SEP) meeting:

Name of SEP: Cancer Drug Discovery:

Diversity Generation and Smart Assays.

Date: December 14–16, 1997.

Time: December 14–7:00 p.m. to Recess,

December 15–8:00 a.m. to Recess, December

16–8:00 a.m. to Adjournment.

Place: Key Bridge Marriott, 1401 Lee

Highway, Arlington, VA 22209.

Contact Person: Ray Bramhall, Ph.D.,

Scientific Review Administrator, National

Cancer Institute, NIH, Executive Plaza North,

Room 643, 6130 Executive Boulevard, MSC

7407, Bethesda, MD 20892–7407, Telephone:

301/496–3428.

Purpose/Agenda: To review, discuss and

evaluate grant applications.

The meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and the discussions could

reveal confidential trade secrets or

commercial property such as patentable

material and personal information

concerning individuals associated with the

applications, the disclosure of which would

constitute a clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer

Detection and Diagnosis Research; 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower;

93.399, Cancer Control)

Dated: November 6, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–29844 Filed 11–12–97; 8:45 am]

BILLING CODE 4140–01–M